Marinus Pharmaceuticals Inc (MRNS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Scott N. Braunstein
Employees:
110
170 N RADNOR CHESTER RD, SUITE 250, RADNOR, PA 19087
484-801-4670

Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.

Data derived from most recent annual or quarterly report
Market Cap 332.629 Million Shares Outstanding47.723 Million Avg 30-day Volume 461.441 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS1.93
Price to Revenue6.1037 Debt to Equity0.621 EBITDA-114.455 Million
Price to Book Value1.389 Operating Margin-442.68780000000004 Enterprise Value-8.961 Million
Current Ratio10.088 EPS Growth0.81 Quick Ratio9.869
1 Yr BETA 1.2859 52-week High/Low 10.29 / 3.47 Profit Margin-77.7769
Operating Cash Flow Growth-103.4825 Altman Z-Score-1.9914 Free Cash Flow to Firm -55.071 Million
Earnings Report2023-05-11

Are you looking for this stock instead?

View SEC Filings from MRNS instead.

View recent insider trading info

Marinus Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MRNS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRNS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-08 by FISCHER SETH H. Z.
  • 4: filed on 2023-02-08 by EZICKSON ELAN
  • 4: filed on 2023-02-08 by AUSTIN CHARLES
  • 4: filed on 2023-01-30 by BRAUNSTEIN SCOTT
  • 4: filed on 2023-01-30 by HULIHAN JOSEPH
  • 4: filed on 2023-01-30 by PFANSTIEL STEVEN
  • 4: filed on 2023-01-30 by SHAFER CHRISTINA
  • 4: filed on 2023-01-30 by MANNING MARTHA E
  • 4: filed on 2023-01-30 by FISCHER SETH H. Z.
  • 4: filed on 2023-01-30 by MAYLEBEN TIMOTHY M

    • Events (8k)

  • 8-K: filed on 2023-03-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-06:
    Item 8.01: Other Events
  • 8-K: filed on 2022-12-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    2.8 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    EZICKSON ELAN

    • Director
    		 5,600 2023-02-06 2

    FISCHER SETH H. Z.

    • Director
    		 6,026 2023-02-06 2

    AUSTIN CHARLES

    • Director
    		 5,277 2023-02-06 2

    MANNING MARTHA E VP, GEN. COUNSEL & CORP. SEC.

    • Officer
    		 109,673 2023-01-26 2

    MAYLEBEN TIMOTHY M

    • Director
    		 33,675 2023-01-26 1

    BRAUNSTEIN SCOTT CHAIRMAN AND CEO

    • Officer
    • Director
    		 527,205 2023-01-26 2

    SILVERSTEIN CHRISTINE BERNI

    • Director
    		 0 2023-01-26 2

    HULIHAN JOSEPH CHIEF MEDICAL OFFICER

    • Officer
    		 165,934 2023-01-26 2

    NOCHUR SARA

    • Director
    		 22,550 2023-01-26 1

    PFANSTIEL STEVEN CHIEF FINANCIAL OFFICER

    • Officer
    		 178,713 2023-01-26 2

    SHAFER CHRISTINA CHIEF COMMERCIAL OFFICER

    • Officer
    		 121,210 2023-01-26 3

    DOUGHERTY MICHAEL R

    • Director
    		 15,687 2022-02-04 0

    VITULLO NICOLE

    • Director
    		 18,817 2022-02-04 0

    ARROYO SANTIAGO

    • Director
    		 15,125 2022-02-04 0

    SMITH EDWARD F FORMER VP, CFO & TREASURER

    • Officer
    		 No longer subject to file 2021-03-09 0

    CARRAZANA ENRIQUE J.

    • Director
    		 0 2021-01-15 0

    LORIANNE MASUOKA K. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-08-21 0

    CASHMAN CHRISTOPHER MICHAEL CEO

    • Officer
    • Director
    		 No longer subject to file 2019-03-18 0

    BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

    BAIN CAPITAL LIFE SCIENCES PARTNERS, LP

    BAIN CAPITAL LIFE SCIENCES FUND, L.P.

    BCIP LIFE SCIENCES ASSOCIATES, LP

    SCHWARTZ JEFFREY LAWRENCE

    KOPPEL ADAM

    • 10% Owner
    		 No longer subject to file 2017-12-15 0

    SHEPARD JAY

    • Director
    		 0 2017-01-17 0

    MEHRA ANAND

    SOFINNOVA VENTURE PARTNERS VI L P

    SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

    SOFINNOVA VENTURE AFFILIATES VI LP

    SOFINNOVA MANAGEMENT VI, L.L.C.

    BUATOIS ERIC

    HEALY JAMES

    AZAN ALAIN

    POWELL MICHAEL

    • 10% Owner
    		 No longer subject to file 2016-10-20 0

    CANAAN VII LP

    CANAAN PARTNERS VII LLC

    • 10% Owner
    		 No longer subject to file 2016-08-05 0

    MEHRA ANAND

    • Director
    		 0 2016-08-03 0

    PATRONEVA ALBENA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-08-03 0

    BLOCH STEPHEN M

    • Director
    		 4,337,346 2015-09-24 0

    FARFEL GAIL M CHIEF CLINICAL DEV & REG OFFIC

    • Officer
    		 8,462 2015-04-21 0

    SHAH NIMESH

    • 10% Owner
    		 42,550 2015-01-01 0

    GOPKA ANTON

    • Director
    		 0 2014-09-30 0

    DOMAIN PARTNERS VI, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 2,476,886 2014-08-05 0

    DP VI ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 17,000 2014-08-05 0

    DOMAIN ASSOCIATES

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    KAMDAR KIM P.

    • Director
    • 10% Owner
    		 42,550 2014-07-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    AUSTIN CHARLES - Director

    		2023-02-08 16:36:05 -0500 2023-02-06 S 1,073 $6.49 d 5,277 direct yes -4.1899 0.419 -13.4078 3.5615 19 -16.2011 29

    FISCHER SETH H. Z. - Director

    		2023-02-08 16:37:47 -0500 2023-02-06 S 1,018 $6.54 d 6,026 direct yes -4.1899 0.419 -13.4078 3.5615 19 -16.2011 29

    EZICKSON ELAN - Director

    		2023-02-08 16:36:40 -0500 2023-02-06 S 750 $6.56 d 5,600 direct yes -4.1899 0.419 -13.4078 3.5615 19 -16.2011 29

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 19:15:05 UTC 3.5502 1.2698 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 18:45:04 UTC 3.5502 1.2698 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 18:15:04 UTC 3.5502 1.2698 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 17:45:04 UTC 3.5502 1.2698 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 17:15:04 UTC 3.5502 1.2698 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 16:45:03 UTC 3.4578 1.3622 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 16:15:04 UTC 3.4578 1.3622 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 15:45:04 UTC 3.4578 1.3622 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 15:15:04 UTC 3.4578 1.3622 700000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 14:45:03 UTC 3.4578 1.3622 700000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 14:15:04 UTC 3.4578 1.3622 700000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 13:45:04 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 13:15:04 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-30 12:45:04 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 22:15:04 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 21:45:05 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 21:15:04 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 20:45:06 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 20:15:05 UTC 3.5659 1.2541 650000
    MARINUS PHARMACEUTICALS INC MRNS 2023-03-29 19:45:05 UTC 3.5659 1.2541 650000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund MRNS -1779.0 shares, $-2739.66 2019-09-30 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund MRNS -1400.0 shares, $-15932.0 2021-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments